Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

被引：95
|
作者：
Llovet, Josep M.
Kudo, Masatoshi
Cheng, Ann-Lii
Finn, Richard S.
Galle, Peter R.
Kaneko, Shuichi
Meyer, Tim
Qin, Shukui
Dutcus, Corina E.
Chen, Erluo
Dubrovsky, Leonid
Zhu, Andrew X.
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Kindai Univ, Sch Med, Osakasayama, Japan
[3] Natl Taiwan Univ Hosp, Ctr Canc, Taipei, Taiwan
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] Johannes Gutenberg Univ Mainz, Med Ctr, Mainz, Germany
[6] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[7] UCL, Inst Canc, London, England
[8] Peoples Liberat Army, Hosp 81, Nanjing, Jiangsu, Peoples R China
[9] Eisai Inc, Woodcliff Lake, NJ USA
[10] Merck & Co Inc, Kenilworth, NJ USA
[11] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS4152
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4152
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Lee Cohn, Allen
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    DiSimone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett, V
    Orlowski, Robert
    Alicia McKenzie, Jodi
    Gillis, Kathryn
    Casado Herraez, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [33] Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)
    Makker, Vicky
    Taylor, Matthew H.
    Aghajanian, Carol
    Oaknin, Ana
    Mier, James
    Cohn, Allen L.
    Romeo, Margarita
    Bratos, Raquel
    Brose, Marcia S.
    Di Simone, Christopher
    Messing, Mark
    Dutta, Lea
    Ren, Min
    Schmidt, Emmett V.
    Orlowski, Robert
    McKenzie, Jodi A.
    Gillis, Kathryn
    Young, Louise
    Herraez, Antonio Casado
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 133 - 134
  • [34] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Kopyltsov, Evgeny
    Mendez Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Gordoa, Teresa Alonso
    Goh, Jeffrey C.
    Merchan, Jaime R.
    Smith, Alan D.
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing Dongyuan
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [35] KEYTRUDA® (Pembrolizumab) plus KISPLYX® (Lenvatinib) - First-Line Treatment of Patients with advanced Renal Cell Carcinoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (1-2) : 70 - 70
  • [36] Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study
    van Laethem, J-L.
    Borbath, I.
    Karwal, M.
    Verslype, C.
    Van Vlierberghe, H.
    Kardosh, A.
    Zagonel, V.
    Stal, P.
    Sarker, D.
    Palmer, D.
    Vogel, A.
    Edeline, J.
    Cattan, S.
    Kudo, M.
    Cheng, A-L.
    Ogasawara, S.
    Siegel, A. B.
    Chisamore, M.
    Wang, A.
    Zhu, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S819 - S819
  • [37] First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study
    Sun, J-M.
    Lin, C-Y.
    Rojas, C.
    Rivera, F.
    Kwong, D.
    Chen, M-H.
    Zhang, Y.
    Yamamoto, S.
    Yu, L.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S863 - S863
  • [38] LEAP-014: first-line lenvatinib plus pembrolizumab plus chemotherapy in advanced/metastatic esophageal squamous cell carcinoma
    Sun, Jong-Mu
    Adenis, Antoine
    C Enzinger, Peter
    Shah, Manish A.
    Kato, Ken
    Bennouna, Jaafar
    Doi, Toshihiko
    Hawk, Natalyn Nicole
    Yu, Li
    Shah, Sukrut
    Bhagia, Pooja
    Shen, Lin
    FUTURE ONCOLOGY, 2024,
  • [39] Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
    Finn, R. S.
    Kudo, M.
    Cheng, A-L.
    Wyrwicz, L.
    Ngan, R.
    Blanc, J-F.
    Baron, A. D.
    Vogel, A.
    Ikeda, M.
    Piscaglia, F.
    Han, K-H.
    Qin, S.
    Minoshima, Y.
    Funahashi, Y.
    Ren, M.
    Dairiki, R.
    Sachdev, P.
    Tamai, T.
    Dutcus, C.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari David
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kraljevic, Silvija
    Ishikawa, Kohei
    Siegel, Abby B.
    Kumada, Hiromitsu
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345